Sven Hoffner spends much of his time researching Mycobacterium tuberculosis, Tuberculosis, Microbiology, Drug resistance and Internal medicine. Sven Hoffner is involved in the study of Mycobacterium tuberculosis that focuses on Pyrazinamide in particular. His work deals with themes such as Global health and Genotype, which intersect with Tuberculosis.
As part of the same scientific family, Sven Hoffner usually focuses on Microbiology, concentrating on Isoniazid and intersecting with Minimum inhibitory concentration. His work carried out in the field of Drug resistance brings together such families of science as Surgery, Rifampicin and Capreomycin. His Internal medicine research is multidisciplinary, incorporating perspectives in Drug susceptibility, Sputum, Pharmacology and Oncology.
Sven Hoffner focuses on Mycobacterium tuberculosis, Tuberculosis, Microbiology, Drug resistance and Virology. Pyrazinamide is the focus of his Mycobacterium tuberculosis research. His Pyrazinamide research includes themes of Moxifloxacin, Ethionamide and Pharmacology.
Sven Hoffner has included themes like Internal medicine and Multiple drug resistance in his Tuberculosis study. His Microbiology research incorporates themes from In vitro and Mycobacterium. His Drug resistance research integrates issues from Immunology, Capreomycin, Rifampicin and Intensive care medicine.
His main research concerns Mycobacterium tuberculosis, Tuberculosis, Drug resistance, Pyrazinamide and Internal medicine. His Mycobacterium tuberculosis research incorporates elements of Genetics, Epidemiology, Virology, Microbiology and Genotype. The Microbiology study combines topics in areas such as Bacilli and In vitro, Structure–activity relationship, Biochemistry.
His Tuberculosis study incorporates themes from Odds ratio, Multiple drug resistance, Cohort study, Infection control and Ofloxacin. His Drug resistance research includes elements of Parasitology, Ethambutol, Rifampicin, Intensive care medicine and Drug. His Pyrazinamide research focuses on subjects like Ethionamide, which are linked to Prothionamide.
Sven Hoffner mostly deals with Mycobacterium tuberculosis, Pyrazinamide, Tuberculosis, Internal medicine and Pharmacology. His Mycobacterium tuberculosis study combines topics from a wide range of disciplines, such as Lineage, Genome, Whole genome sequencing and Drug resistance, Microbiology. His biological study spans a wide range of topics, including Rifampicin and Capreomycin.
His studies in Pyrazinamide integrate themes in fields like Moxifloxacin and Ethionamide. His Tuberculosis study integrates concerns from other disciplines, such as Multiple drug resistance, Retrospective cohort study, Molecular epidemiology, Genotype and Family history. The study incorporates disciplines such as Ofloxacin, Bedaquiline and Environmental health in addition to Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
Koen Andries;Peter Verhasselt;Jerome Guillemont;Hinrich W. H. Göhlmann.
Global trends in resistance to antituberculosis drugs.
Marcos A. Espinal;Adalbert Laszlo;Lone Simonsen;Fadila Boulahbal.
The New England Journal of Medicine (2001)
Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage
Matthias Merker;Camille Blin;Stefano Mona;Nicolas Duforet-Frebourg.
Nature Genetics (2015)
Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis
Deneke H. Mariam;Yohannes Mengistu;Sven E. Hoffner;Dan I. Andersson.
Antimicrobial Agents and Chemotherapy (2004)
Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis.
Freddie Bwanga;Freddie Bwanga;Sven Hoffner;Melles Haile;Moses L Joloba.
BMC Infectious Diseases (2009)
Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages
David Stucki;David Stucki;Daniela Brites;Daniela Brites;Leïla Jeljeli;Mireia Coscolla;Mireia Coscolla.
Nature Genetics (2016)
Extensively Drug-Resistant Tuberculosis: 2 Years of Surveillance in Iran
Mohamad Reza Masjedi;Parissa Farnia;Setara Sorooch;Majid Valiollah Pooramiri.
Clinical Infectious Diseases (2006)
Origin and primary dispersal of the Mycobacterium tuberculosis Beijing genotype: Clues from human phylogeography
Igor Mokrousov;Ho Minh Ly;Tatiana Otten;Nguyen Ngoc Lan.
Genome Research (2005)
Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrB
Andrea Von Groll;Anandi Martin;Pontus Jureen;Sven Hoffner.
Antimicrobial Agents and Chemotherapy (2009)
Microevolution of extensively drug-resistant tuberculosis in Russia
Nicola Casali;Vladyslav Nikolayevskyy;Yanina Balabanova;Olga Ignatyeva.
Genome Research (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: